Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms

Project description

A new type of ring may soon be grabbing men's attention

The prostate gland produces the seminal fluid that nourishes and transports sperm. In most men, it continues to grow throughout life. In many, it enlarges enough to cause urinary symptoms. Treatment options range from medication to surgery including transurethral interventions, laser ablation, and even prostatectomy. ProArc has developed a minimally invasive solution that promises enhanced quality of life and health for millions. ClearRing is an implantable device that restores free passage of fluid. It can be placed during an out-patient visit in a completely reversible procedure for the immediate relief of symptoms with the total preservation of sexual function. EU funding of the ClearRing project is supporting large-scale randomised clinical trials to bring easy, affordable and efficacious treatment to patients.

Objective

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications.
ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function.
Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

PROARC MEDICAL LTD
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 943 725,00
Address
KIDMA 23
3707923 PARDES HANA
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 776 750,00
My booklet 0 0